Magnesium

QUICK REFERENCE Evidence: 5/5 (multiple meta-analyses, 898 registered trials) Dose: 200-400mg elemental/day (form-dependent) Timing: Evening for sleep (glycinate); AM for cognition (threonate); with meals for tolerance Lab target: Serum Mg 0.85-0.95 mmol/L; RBC Mg 2.2-2.8 mmol/L (more accurate) Monitor: Serum Mg baseline + 3mo; renal function if >600mg/day or elderly Key interactions: Levothyroxine (space 4h), bisphosphonates (space 4h), quinolone antibiotics (space 6h) STATUS: Essential mineral. GRAS (US). OTC supplement worldwide.

Clinical Summary

Magnesium is the fourth most abundant mineral in the body and a cofactor in 600+ enzymatic reactions including ATP synthesis, protein synthesis, neurotransmitter regulation, and blood pressure control. Total body content is 21-28g, with 99% intracellular (50-60% bone, 39% soft tissue, <1% extracellular). Serum Mg is a poor indicator of status — only 1% of body Mg is in blood.

Deficiency is common: 50-60% of US adults consume less than the EAR. Subclinical deficiency affects 30-50% of Western populations. High-risk groups: T2D (25-38%), elderly (20-30%), PPI users (10-20%), IBD (13-88%), chronic alcoholics (30-80%).

Why it matters: Strong evidence (multiple meta-analyses) for blood pressure reduction, migraine prevention, preeclampsia treatment, and glycemic control in deficient diabetics. Moderate evidence for sleep quality and anxiety. Safety profile is excellent — wide therapeutic index, self-limiting laxative effect prevents oral overdose in those with normal renal function. The primary safety gate is kidney function (GFR <30 = contraindicated).

Key mechanisms: NMDA receptor antagonism (migraine, neuroprotection), calcium channel blocking (vasodilation, BP), ATP-Mg complex (energy metabolism), GABA modulation (sleep, anxiety), vascular smooth muscle relaxation (blood pressure), insulin receptor tyrosine kinase cofactor (glucose metabolism).

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend: 5/5 = Multiple large RCTs + meta-analyses | 4/5 = Several human RCTs | 3/5 = Some human pilot/limited RCT | 2/5 = Very limited human or negative RCTs | 1/5 = No evidence or debunked

Prescribing

Dosing Table

RDA: Men 400-420mg/d, Women 310-320mg/d (IOM). UL from supplements: 350mg/d (does not apply to food sources).

Formulation Table

Condition-Specific Protocols

Hypertension Protocol

Evidence: 5/5 | PMID 41000008 (38 RCTs, N=2709)

Phase 1: Initiation (Weeks 1-4)

• 200-300mg elemental Mg (citrate, glycinate, or taurate), evening dose
• Baseline: serum Mg, BP log (2x daily), renal function
• Goal: Assess tolerance, establish routine

Phase 2: Therapeutic (Weeks 5-24)

• 300-500mg/d, divided if >400mg
• Monitor BP weekly; expected SBP -2.8 mmHg overall, up to -7.7 mmHg in treated hypertensives
• Synergistic stack: Potassium 2-3g/d + Omega-3 2-3g EPA+DHA + Coenzyme-Q10 100-200mg

Phase 3: Maintenance (Week 24+)

• Continue 300-400mg/d indefinitely
• BP monitoring monthly; Mg levels annually

Expected Outcomes: SBP -2.8 to -7.7 mmHg depending on baseline status. Greater effect in hypomagnesemic and treated hypertensives. Normotensive populations may not reach significance. Stop/Reassess: If no BP change at 24 weeks despite confirmed intake.

Migraine Prevention Protocol

Evidence: 5/5 | PMID 39404918 (22 RCTs, dose-response MA)

Phase 1: Initiation (Weeks 1-4)

• 200mg 2x/d (citrate or glycinate)
• Track migraine diary: frequency, duration, severity

Phase 2: Therapeutic (Weeks 5-12)

• 400-600mg/d divided doses for steady-state levels
• DO NOT assess efficacy before 12 weeks — this is the minimum for preventive effect
• Expected: -2.5 attacks/month, 41% frequency reduction, 40% duration reduction

Phase 3: Maintenance (Month 3-12+)

• Continue effective dose; annual reassessment
• If effective, maintain indefinitely; no tolerance develops

Drug Interaction Timing: Space 2h from triptans (no direct interaction but good practice) Acute migraine: IV MgSO4 1-2g over 15-30 min (30-50% response rate, especially migraine with aura)

Type 2 Diabetes Protocol

Evidence: 4/5 (in deficient) | PMID 27530471 (18 RCTs, N=1126)

Phase 1: Baseline Assessment

• Serum Mg + RBC Mg + HbA1c + fasting glucose + HOMA-IR
• If Mg-replete (>0.85 mmol/L): standard 200-300mg maintenance only (minimal additional benefit)

Phase 2: Therapeutic (Mg-deficient T2D)

• 300-500mg/d with meals (glycinate or citrate)
• 12-24 weeks for metabolic improvements
• Expected: FBG -4.6 mg/dL, HbA1c -0.3-0.5%, HOMA-IR improvement 20-30%
• Natural experiment validation: Gitelman syndrome proves Mg depletion drives insulin resistance (PMID 40164390)

Phase 3: Maintenance

• 300-400mg/d indefinitely; recheck HbA1c and Mg at 6 months
• NOT a substitute for metformin/insulin

Synergistic: Vitamin D3 2000-4000 IU + Chromium 200-400mcg + Berberine 1500mg

Safety

Interactions Table

Contraindications

Absolute:

• Severe renal impairment (GFR <30 mL/min) — hypermagnesemia risk
• Myasthenia gravis — worsens neuromuscular weakness
• Complete heart block (without pacemaker) — further slows conduction
• Bowel obstruction — peristalsis worsens obstruction

Relative (caution + monitoring):

• Moderate renal impairment (GFR 30-60) — reduce dose, monitor monthly
• Hypotension (SBP <90) — further BP lowering
• Bradycardia (<50 bpm) — may slow rate further
• Active severe diarrhea — avoid citrate/oxide; use glycinate only

Adverse Effects

Therapeutic index: Wide. Effective: 200-600mg/d. Toxic: >3000-5000mg/d in normal renal function (>10x therapeutic). Laxative effect self-limits oral intake. Serious toxicity only with IV overdose or severe renal failure.

FAERS Signal Table

FAERS interpretation: The 729K FAERS reports for "magnesium" are dominated by pharmaceutical magnesium salt formulations — esomeprazole magnesium (Nexium), IV MgSO4, bowel prep solutions, and dialysis solutions. These do NOT represent the safety profile of oral magnesium supplementation. Diarrhea is the only pharmacologically expected AE from oral supplementation (osmotic effect, especially citrate/oxide). No novel safety signals for supplemental magnesium identified as of 2026-04.

Monitoring Table

Special Populations

Renal Impairment

CKD safety signal: Large Taiwanese cohort (PMID 41938509, N=16,248) found MgO use in CKD associated with increased AKI (aHR 37.0), ESRD (aHR 3.13), cardiac arrhythmia (aHR 2.06). Likely confounded by indication (sicker patients prescribed more MgO), but reinforces that renal impairment is the primary safety gate for Mg supplementation.

Pregnancy & Lactation

FDA former Category A (adequate well-controlled studies show no risk). Safe at 200-450mg/d throughout pregnancy. IV MgSO4 is standard treatment for eclampsia/preeclampsia. Lactation: safe; does not significantly increase breast milk Mg.

Synergies & Stacking

Antagonistic interactions (space 2-3h):

• Calcium — competes for TRPM6 transporters (↓Mg absorption 30-40% at >500mg Ca)
• Iron — competitive DMT1 inhibition (take Iron AM, Mg PM)
• Zinc (>30mg) — competitive absorption inhibition
• High-fiber/phytate meals — bind Mg in GI tract (10-20% reduction)

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No other pharmacogenomic modifiers have been established for magnesium supplementation. TRPM7 genotyping for Mg response is an emerging research area (Vanderbilt group, Dai Q et al.) but not yet clinically actionable.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Strongly positive across ~thousands of posts (Reddit r/Nootropics, r/Supplements, r/Sleep, r/Anxiety; Longecity; Mayo Clinic Connect). Estimated 70-75% positive, 15% mixed, 10% negative.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• BiOptimizers "Magnesium Breakthrough": Aggressive influencer marketing (not MLM, but heavy affiliate model). "7 forms in one capsule" is marketing differentiation with no evidence of superiority. Customer reports of damaged capsules. Premium pricing ($40-50) for a commodity mineral.
• Influencer concentration: Andrew Huberman's sleep stack created disproportionate demand for threonate. The stack is functional but inflated threonate's profile vs cheaper, equally effective glycinate for sleep.
• Instagram supplement influencers: Only 2% disclose possible adverse effects for products they promote. Instagram is a "highly unreliable source of safe supplement information."
• No MLM involvement: Magnesium is not primarily sold through MLM channels (unlike many supplements).
• Astroturfing risk: Some "Mg changed my life" posts on Reddit have suspiciously similar phrasing; most appear genuine given the compound's real efficacy.

Folk vs Clinical Reality Check

Community experience strongly aligns with clinical data for sleep, anxiety, and muscle cramps — these are the most commonly reported benefits in both contexts. The main divergence is that community often overstates cognitive benefits of glycinate (attributing it to NMDA effects when the clinical data is stronger for threonate). The folk dosing consensus (200-400mg) closely matches clinical recommendations, which is unusual for supplement communities. The Gwern blinded N=1 experiment is the most rigorous community evidence and supports the clinical dose range — benefit at ~130mg, harm at ~800mg.

Deep Dive: Mechanisms & Research

Key Mechanisms with Clinical Translation

NMDA Receptor Antagonism (Clinical translation: YES) Blocks calcium influx through NMDA receptors, preventing excitotoxicity. Drives migraine prevention (cortical spreading depression inhibition), neuroprotection, and anxiolytic effects. Clinical confirmation via migraine RCTs and IV use for acute migraine with aura.

Calcium Channel Blocking (Clinical translation: YES) Antagonizes calcium entry into vascular smooth muscle → vasodilation → BP reduction. Confirmed in 38 RCTs (PMID 41000008). Also stabilizes cardiac membranes (arrhythmia use).

ATP-Mg Complex (Clinical translation: PARTIAL) All ATP exists as Mg-ATP. Required for glycolysis, Krebs cycle, oxidative phosphorylation. Explains theoretical energy benefits but new evidence (PMID 40077784) shows supplementation may DECREASE VO2max and sprint power in non-deficient exercisers — suggesting exogenous Mg may downregulate mitochondrial complex II with fatty acid substrates.

Insulin Receptor Tyrosine Kinase Cofactor (Clinical translation: YES in deficient) Required for tyrosine kinase activity and GLUT4 translocation. Confirmed in RCTs (deficient T2D) and Gitelman syndrome natural experiment (PMID 40164390).

GABA Modulation (Clinical translation: PARTIAL) Enhances GABAergic signaling → calming, sleep promotion. Sleep RCTs positive but mostly in elderly. Glycine component of glycinate adds additional inhibitory neurotransmitter effect.

Gut Microbiome Modulation (Clinical translation: EMERGING) Precision RCT (PMID 40946805, N=240) showed Mg increases C. maltaromaticum and F. prausnitzii (vitamin D-synthesizing, CRC-inhibiting species). Effect is TRPM7 genotype-dependent and primarily observed in females. This is the first evidence linking Mg to microbiome-mediated cancer prevention.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Total registered trials (condition=magnesium): 898 | Completed: 488 | Recruiting: 71 Notable: Cochrane systematic review on Mg for migraine prophylaxis is in progress (PMID 41216917 — protocol published 2025).

Regulatory Status

• US FDA: GRAS (Generally Recognized as Safe). Regulated as dietary supplement under DSHEA 1994. No standalone NDA. Magnesium salts appear in pharmaceutical formulations (esomeprazole Mg, bowel preps).
• EU (EMA): No centralized authorization. Regulated as food supplement under Directive 2002/46/EC. EFSA-authorized health claims.
• Japan: Regulated as food supplement. 350mg/d UL. MgO widely physician-prescribed for constipation.
• South Korea: Regulated as health functional food ingredient. 350mg/d UL.

Key New Findings (2024-2026)

Changes existing knowledge:

1. ICU arrhythmia prevention debunked (PMID 41359319, JAMA Intern Med 2026): 478K ICU treatment windows, no benefit of routine Mg repletion for tachyarrhythmia, hypotension, or death
2. Hypermagnesemia harmful in HFrEF (PMID 40886161, EHJ 2026): In 6,147 HFrEF patients, hypermagnesemia (not hypomagnesemia) had worst outcomes
3. TRPM7 genotype determines Mg response (PMID 40946805, AJCN 2025): First precision RCT — Mg gut microbiome benefits are genotype-dependent
4. Mg may be ergolytic in replete athletes (PMID 40077784, 2025): Decreased VO2max (-3.1 mL/kg/min) and sprint power in non-deficient exercisers
5. MgO hazardous in CKD (PMID 41938509, 2026): Taiwanese cohort shows dramatically elevated renal and cardiac risks

Confirms existing knowledge:

1. BP meta-analysis updated: -2.8/-2.1 mmHg overall, -7.7 in treated hypertensives (PMID 41000008)
2. Migraine dose-response confirmed in 22-RCT MA (PMID 39404918)
3. Diabetes-mortality: HR 0.62 all-cause, 0.54 CVD mortality in highest Mg quartile (PMID 41578652)
4. Mg-L-Threonate cognition/sleep RCT positive (PMID 41601871)
5. Mg bisglycinate sleep RCT positive (PMID 40918053)
6. Mg as SSRI adjunct: large effect size for depression (PMID 41916937)

Ataraxia Verdict (as of 2026-04-16)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

False precision (MEDIUM): File previously presented bioavailability percentages (e.g., "40-50% for glycinate") with more confidence than the small studies (N<50) warrant. These are reasonable estimates but not precise measurements.

Cherry-picking (MEDIUM): The anxiety claim (d=0.52) originates from a meta-analysis of "antioxidant supplements including magnesium" — not magnesium alone. The isolated Mg effect size is unclear.

Appeal to popularity (LOW): "50-60% are deficient" is used to justify universal supplementation. While deficiency IS common, this doesn't automatically mean every individual benefits from supplementation.

Overall hype level: LOW. Magnesium is one of the least overhyped supplements. Most claims are backed by genuine RCT evidence. The main inflation is in peripheral claims (cognition, athletic performance, hair/skin) where evidence is thin.

Evidence Gaps

1. Head-to-head formulation comparisons: No RCTs comparing glycinate vs citrate vs threonate directly. Bioavailability data from small studies.
2. Young adult sleep data: Most sleep RCTs in elderly (>65). Limited evidence in 25-50 age range.
3. Long-term safety (>5 years): Most RCTs are 8-24 weeks. Decades of clinical use is reassuring but not trial-proven.
4. Genetic precision dosing: TRPM6/TRPM7 polymorphisms affect response but clinical testing unavailable.
5. Depression monotherapy: New adjunctive RCT is promising (PMID 41916937) but N=40 and needs replication.
6. Microbiome interactions: Single precision RCT (PMID 40946805) is landmark but needs replication.
7. Hair/skin/eye health: Zero human clinical evidence for any dermatological or ophthalmological benefit.
8. Sex-specific pharmacokinetics: No dedicated studies despite known differences in RDA and enzyme expression.
9. Longevity/senescence: Zero direct evidence. Only indirect mortality data from observational cohorts in diabetes.
10. Pediatric dosing: Extrapolated from adults; few pediatric RCTs.

Bias Flags (Mode 4: First Principles)

Assumption: "More bioavailable = better" — Higher absorption doesn't mean better clinical outcomes. MgO's low absorption IS the desired mechanism for constipation. Threonate's brain penetration is marketed heavily but clinical translation beyond one RCT is limited.

Assumption: "Serum Mg reflects status" — Only 1% of body Mg is extracellular. Normal serum does not exclude tissue deficiency. RBC Mg is better but not widely available. This means both deficiency prevalence AND treatment response are harder to assess than typically presented.

Assumption: "Universal supplementation is justified" — Based on population-level deficiency data. Individual assessment might be more appropriate. New evidence that Mg can be ERGOLYTIC in replete athletes (PMID 40077784) challenges the "more is better" assumption.

What survives scrutiny: The essential nature of Mg, widespread dietary insufficiency, BP and migraine benefits, and the safety profile in normal renal function are all well-grounded in multiple independent lines of evidence.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Supplement industry promotes premium forms (glycinate, threonate) at 3-5x the cost of basic forms. The "7 forms" marketing (BiOptimizers) has no evidence base. Form-specific claims are often extrapolated from mechanism rather than head-to-head trials.
• Influencer economics: Andrew Huberman's Mg threonate endorsement drives significant sales; he does not have direct financial ties to Magtein but the recommendation has commercial downstream effects. BiOptimizers runs large-scale affiliate programs with health influencers.
• Counter-narrative manipulation: Minimal. No significant pharma interest in suppressing Mg supplementation (not a competitor to major drug classes except mildly for sleep aids and BP meds).
• Cui bono summary: Supplement manufacturers (especially premium forms) benefit from supplementation. Pharmaceutical companies have minimal competing interest. The individual genuinely benefits if deficient (50-60% of population). The alignment between commercial and health interests is better than for most supplements.
• Red team highlight: The most concerning angle is the assumption that oral supplementation effectively corrects tissue deficiency when serum monitoring is acknowledged as inadequate. If 1% of body Mg is in blood, how do we know our supplements are reaching muscle, bone, and brain?

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 9/10 — essential mineral with 5/5 evidence across cardiovascular, metabolic, sleep, neuromuscular, and bone domains; 50-60% of adults subclinically deficient, exceptional safety profile, and very broad indication breadth.
• Opportunity cost: Minimal — low cost ($10-30/mo), excellent safety, no known downside in appropriate dose for those with normal renal function
• Verdict: ADD
• Rationale: Strong evidence for multiple 5/5 indications, 50-60% of adults are subclinically deficient, exceptional safety profile, low cost. One of the most evidence-supported supplements available. The only population that should NOT supplement is those with GFR <30 or replete athletes seeking performance enhancement.

Bottom Line

Magnesium is one of the best-supported supplements in existence. The evidence base — 898 registered trials, 15+ meta-analyses, decades of clinical use — puts it in a different league from most nutraceuticals. Blood pressure reduction and migraine prevention are backed by multiple large meta-analyses. Sleep and anxiety benefits are real but more modest and population-specific (strongest in elderly and Mg-deficient). The major 2024-2026 updates: (1) routine ICU Mg repletion for arrhythmia is now debunked by a large quasi-experiment, (2) Mg may actually impair athletic performance in non-deficient exercisers, (3) TRPM7 genotype determines gut microbiome response — opening the door to precision Mg dosing. Safety is excellent with renal function as the sole meaningful gate. Cost is low. The decision to supplement is straightforward for anyone in the 50-60% of adults who are subclinically deficient.

Practical Notes

Brands & Product Selection

USP Verified: Nature Made, Kirkland Signature (Costco) — gold standard for quality assurance. NSF Certified: Thorne Research (athletes), Pure Encapsulations (hypoallergenic), NOW Foods (value). Other third-party tested: Life Extension, Jarrow Formulas, Doctor's Best, Klaire Labs.

Quality markers: USP or NSF seal; Certificate of Analysis available on request; heavy metals tested (Pb <0.5ppm, Cd <0.5ppm); lot numbers and expiration dates present. Red flags: No third-party testing, proprietary blends hiding Mg amounts, MLM distribution, claims like "cures diabetes," price >60% below market average.

Storage & Handling

Room temperature (15-25°C), protected from direct sunlight, airtight container, keep dry (desiccant in humid climates). Shelf life: 2-3 years unopened, 18-24 months after opening. No refrigeration needed. Do not store in bathroom (moisture).

Palatability & Compliance

Glycinate: nearly tasteless (best for powders). Citrate: sour/tart (mix with citrus juice). Oxide: chalky (avoid in powder form). Powder forms allow dose titration and are 30-50% cheaper than capsules. Mix with orange juice, smoothies, or protein shakes.

Exercise & Circadian Timing

Pre-workout (60-90 min): 200-300mg glycinate or malate. Avoid citrate (laxative risk during exercise). Caution: New evidence shows Mg may decrease VO2max in non-deficient exercisers (PMID 40077784) — supplementation primarily indicated for athletes with confirmed deficiency. Post-workout: 300-400mg glycinate or taurate (replaces sweat losses, supports recovery). Evening (1-2h before bed): 300-500mg glycinate — optimal timing for sleep benefit. Morning: Threonate for cognitive enhancement; malate for energy. Divided dosing: Split if >400mg/d total (better absorption, fewer GI effects).

Reference Ranges (Expected Biomarker Changes)

Cost

True cost per 100mg absorbed: Citrate $0.29/d, Glycinate $0.36/d, Oxide $0.75/d (poor bioavailability makes oxide cost-ineffective despite low price).

What We Don't Know

• Optimal form for each specific indication (no head-to-head formulation RCTs)
• Whether non-deficient individuals benefit from supplementation (most positive trials in deficient populations)
• How TRPM6/TRPM7 genetic variants should modify clinical dosing (emerging data, no clinical testing)
• Long-term (>5 year) effects from RCTs (only observational data beyond 2 years)
• Why Mg supplementation may be ergolytic in replete athletes (decreased VO2max mechanism unclear)
• Whether Mg-microbiome-CRC axis (PMID 40946805) replicates and has clinical utility
• Adequate pediatric dosing protocols (extrapolated from adults)
• Whether serum Mg monitoring is adequate or if routine RBC Mg should be standard
• Sex-specific dose-response curves (no dedicated PK studies)
• Whether the new depression adjunctive signal (PMID 41916937, N=40) will replicate in larger trials

References

Systematic Reviews & Meta-Analyses

1. Argeros Z et al. (2025). Magnesium supplementation and blood pressure. Hypertension. 38 RCTs, N=2709. SBP -2.81 mmHg, DBP -2.05 mmHg; -7.68 in treated HTN. PMID: 41000008
2. Zhang X et al. (2016). Effects of Mg on BP: meta-analysis of 34 RCTs. Hypertension 68(2):324-333. SBP -3.06, DBP -2.11. PMID: 27402922
3. Talandashti MK et al. (2025). Dietary supplements for migraine prophylaxis: dose-response MA. Neurol Sci. 22 RCTs. Mg: -2.51 attacks, -0.88 severity. PMID: 39404918
4. Chiu HY et al. (2016). Oral Mg for migraine: RR 0.41. Cephalalgia. PMID: 26752497
5. Teigen L, Boes CJ. (2015). Mg for migraine prevention: 41.6% reduction. Cephalalgia 35(10):912-922. PMID: 25533715
6. Veronese N et al. (2016). Mg on glucose metabolism. 18 RCTs, N=1126. FBG -4.6 mg/dL. Eur J Clin Nutr. PMID: 27530471
7. Fang X et al. (2016). Dietary Mg and CV/diabetes risk: dose-response MA. 40 cohorts, >1M participants. 22% ↓HF risk per 100mg/d. BMC Med. PMID: 27927203
8. Boyle NB et al. (2017). Mg on anxiety and stress: d=0.52. Nutrients 9(5):429. PMID: 28445426
9. Mah J, Pitre T. (2021). Mg for sleep in older adults: systematic review. PMID: 33865376
10. Garrison SR et al. (2012). Mg for muscle cramps: Cochrane Review. No significant benefit in general population. PMID: 22972143
11. von Luckner A, Riederer F. (2018). Mg for migraine prophylaxis: Grade C evidence. PMID: 29131326
12. Hofmeyr GJ et al. (2014). Ca/Mg during pregnancy for hypertensive disorders. Cochrane. PMID: 24960615
13. Hariri M et al. (2025). Mg and lipid profile: dose-response MA. Nutr J. PMID: 39905454
14. Behers BJ et al. (2024). Mg + K for SBP in normotensives. Nutrients. PMID: 39519450
15. Amer SA et al. (2025). Ca, Mg, Vitamin D for hypertension. BMC Complement Med Ther. PMID: 40045266
16. Abu-Zaid A et al. (2025). Mg on PCOS: no significant effects on cardiometabolic/hormonal parameters. Medicina. PMID: 40005397
17. Rodriguez JP et al. (2025). Cochrane protocol: Mg for migraine prophylaxis (review in progress). PMID: 41216917

Landmark RCTs & Clinical Trials

18. Goulden R et al. (2026). Mg supplementation and tachyarrhythmias. 478K ICU windows, 93 ICUs. No benefit for routine repletion. JAMA Intern Med. PMID: 41359319
19. Walyddaini AS et al. (2026). Mg adjunct to fluoxetine for depression. N=40. HDRS -6.35 vs -2.80. East Asian Arch Psychiatry. PMID: 41916937
20. Sun E et al. (2025). Mg increases gut vitamin D-synthesizing bacteria; TRPM7 genotype-dependent. N=240. Am J Clin Nutr. PMID: 40946805
21. Bomar MC et al. (2025). Short-term Mg: ↓VO2max, ↓sprint power in non-deficient exercisers. Nutrients. PMID: 40077784
22. ELDerawi WA et al. (2018). 250mg Mg/d improved HOMA-IR in T2D. Diabetes Metab Syndr Obes. PMID: 30587761
23. Abbasi B et al. (2012). Mg 500mg/d improved sleep in elderly. N=46. J Res Med Sci. PMID: 23853635
24. PMID: 40918053 — Mg bisglycinate for poor sleep: RCT, placebo-controlled. Nat Sci Sleep. 2025.
25. PMID: 41601871 — Mg-L-Threonate (Magtein) on cognition and sleep: double-blind RCT. Front Nutr. 2025.
26. PMID: 41756632 — Oral Mg improves glycemic control in pre-diabetes with hypomagnesemia (China). Front Nutr. 2026.
27. PMID: 39202546 — Deep seawater Mg vs insulin resistance in pre-diabetics (Korea). N=75. Medicina. 2024.
28. PMID: 38564107 — Mg for cisplatin nephrotoxicity in pediatric cancer (Japan). Phase 2 RCT. Int J Clin Oncol. 2024.
29. Khalid S et al. (2024). Mg/K supplementation reduces insomnia in diabetics. N=320. Front Endocrinol. PMID: 39534260
30. PMID: 40537122 — Topical Mg gel: no effect on exercise recovery. Int J Sport Nutr Exerc Metab. 2025.
31. Liu CJ et al. (2021). Mg for pregnancy leg cramps: no significant benefit. PMID: 34247796

Safety & Population Studies

32. Hsiao PJ et al. (2026). MgO in CKD: ↑AKI (aHR 37.0), ↑ESRD (aHR 3.13), ↑arrhythmia (Taiwan). N=16,248. Int J Med Sci. PMID: 41938509
33. Chimura M et al. (2026). Hypermagnesemia worst outcomes in HFrEF. N=6,147. Eur Heart J. PMID: 40886161
34. Chi K et al. (2026). Mg and mortality in diabetes: HR 0.62 all-cause (US+UK). Diabet Med. PMID: 41578652
35. Wester PO. (1987). Mg safety review. Wide margin of safety in normal renal function. PMID: 3034044
36. Volpe SL. (2013). Long-term Mg safe up to 600-800mg/d in healthy. Adv Nutr. PMID: 23674807

Mechanism & Review

37. Gröber U et al. (2015). Mg in prevention and therapy. 600+ enzymatic reactions. Nutrients. PMID: 26404370
38. Maier JA et al. (2020). Mg and inflammation: NF-κB, oxidative stress. Front Immunol. PMID: 32793247
39. Guerrera MP et al. (2009). Therapeutic uses of Mg. Am Fam Physician. PMID: 19621856
40. Rosanoff A et al. (2012). 50-60% of US adults below EAR. Nutr Rev. PMID: 22364157
41. Costello RB et al. (2016). Evidence-based serum Mg reference interval: 0.85-0.95 mmol/L. Adv Nutr. PMID: 28140320
42. Xin Y et al. (2025). Gitelman syndrome proves Mg depletion drives IR. Diabetes Res Clin Pract. PMID: 40164390
43. Cao X et al. (2025). TRPM6/7 polymorphisms and gestational DM. J Nutr Biochem. PMID: 40803545
44. Sun S et al. (2025). TRPM7 genotype affects gut microbiota and polyp risk. J Nutr. PMID: 40750038
45. Guzman-Esquivel J et al. (2025). Hypomagnesemia predicts post-COVID cognitive impairment. Med Sci. PMID: 40843737

Bioavailability Studies

46. Walker AF et al. (2003). Mg citrate more bioavailable than oxide. N=10. Magnes Res. PMID: 14596323
47. Coudray C et al. (2005). Organic Mg salts 30-40% bioavailability vs inorganic in animals. Magnes Res. PMID: 16548135
48. Firoz M, Graber M. (2001). Bioavailability of commercial Mg: chelates superior to oxide. Magnes Res. PMID: 11794633

Disease-Specific

49. Gilca-Blanariu GE et al. (2022). Mg in IBD: 13-88% deficiency. Magnes Res. PMID: 35565881
50. Galland L. (1988). Mg deficiency in IBD. PMID: 3294519
51. Nielsen FH et al. (2010). Mg 320mg/d improved sleep and reduced CRP in older adults. PMID: 21199787
52. Chacko SA et al. (2010). Dietary Mg and inflammation/endothelial dysfunction. Diabetes Care. PMID: 19903755
53. Li S et al. (2025). MDS predicts osteoporosis in elderly (NHANES). OR 1.27. Magnes Res. PMID: 41395732
54. Wang J et al. (2022). Antioxidants including Mg for anxiety. Front Nutr. PMID: 36442656
55. Yahyavi SK et al. (2026). Serum Mg linked to sperm quality. Reprod Biomed Online. PMID: 41653852

Epidemiology & Guidelines

56. IOM Standing Committee. (1997). DRI for Mg: 310-420mg/d adults; UL 350mg/d supplements. National Academies Press.
57. Moshfegh A et al. (2009). 60% of US adults below RDA. NHANES 2005-2006. USDA.
58. Fang X et al. (2016). Dose-response meta-analysis >1M participants. BMC Med. PMID: 27927203
59. Lin Y et al. (2025). MDS ≥3: HR 1.47 all-cause mortality in diabetics. J Trace Elem Med Biol. PMID: 40992112